In Brief: InSite Vision/Bausch & Lomb
Executive Summary
InSite Vision/Bausch & Lomb: Announce global agreement covering the manufacturing of potential InSite Vision products, the worldwide marketing of PilaSite (pilocarpine) for glaucoma and joint development of the DuraSite eyedrop-based sustained drug delivery system. B&L will make a $2 mil. equity investment, provide up to $2 mil. in R&D funding and pay royalties on future products. PilaSite and BetaSite (levobunolol) for glaucoma both have completed Phase III trials, Alameda, Calif.-based InSite notes; the B&L deal will allow the products to proceed to NDA filings "without incurring substantial infrastructure costs required to develop our own large-scale production facilities," InSite notes...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth